RxSight Inc. Common Stock Q3 2025 Earnings Recap

RXST Q3 2025 November 6, 2025

Get alerts when RXST reports next quarter

RxSight's Q3 2025 performance highlighted strategic initiatives for growth despite a revenue decline, with notable shifts in product mix contributing to improved gross margins.

Earnings Per Share Beat

$-0.04 vs $-0.19 est.

+78.9% surprise

Revenue Miss

30340000 vs 32602350 est.

-6.9% surprise

Market Reaction

1-Day +3.24%

5-Day +22.66%

30-Day +39.69%

See RXST alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q3 2025 revenue decreased to $30.3 million, down 14% year-over-year and 10% sequentially, largely driven by lower LDD sales.
LAL revenue grew 6% year-over-year, constituting 85% of total revenue, reflecting strong demand and engagement from ophthalmologists.
Gross margin improved significantly to 79.9%, benefiting from a higher percentage of LAL sales and reduced unit costs.
The company narrowed its full-year revenue guidance to $125 million to $130 million, indicating a cautious but optimistic outlook.
Cash reserves remained stable at $227.5 million, providing a solid foundation for ongoing strategic initiatives and growth plans.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit RXST on AllInvestView.

Next Q1 2026